Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-959-5 | CAS number: 7782-50-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1999
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Publicly avaialble literature, non GLP
Cross-reference
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 999
Materials and methods
- Objective of study:
- distribution
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Guideline or Method not indicated.
- GLP compliance:
- no
Test material
- Reference substance name:
- Chlorine
- EC Number:
- 231-959-5
- EC Name:
- Chlorine
- Cas Number:
- 7782-50-5
- Molecular formula:
- Cl2
- IUPAC Name:
- dichlorine
- Details on test material:
- chlorine
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- human
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Five males, five females, non-smokersAge: 18-36 years (mean: 24.7±5.4 years)Weight: 55.1-94.8 kg (mean: 71.4±13.8 kg)
Administration / exposure
- Route of administration:
- inhalation
- Vehicle:
- other: air
- Details on exposure:
- The bolus inhalation session comprised three experiments:oral breathing with a peak concentration of 3.0 ppmnasal breathing with a peak concentration of 3.0 ppmnasal breathing with a peak concentration of 0.5 ppm
- Duration and frequency of treatment / exposure:
- 2-4h
Doses / concentrations
- Remarks:
- Doses / Concentrations:10 mL Cl2 bolus was injected into the airflow
- No. of animals per sex per dose / concentration:
- 5
- Control animals:
- not specified
- Positive control reference chemical:
- no positive control
- Details on study design:
- To observe the longitudinal distribution of Cl2 absorption in intact human airways during quiet breathing the non-invasive bolus inhalation method previously developed for ozone was employed. The apparatus could deliver Cl2 boluses and continuously monitor the Cl2 concentration. By using the apparatus, bolus measurements were compared during nasal and oral breathing to determine whether the site of air access influenced the penetration of Cl2 beyond the upper airways. Bolus inhalation measurements: All 10 volunteers participated in a 2- to 4-h session in which bolus measurements were made during nasal and oral quiet breathing. The person was seated comfortably on a stool, wore noseclips during oral breathing, and maintained a closed mouth during nasal breathing. The subject controlled his or her breathing so that the respired volume signal followed a pre-drawn pattern corresponding to equal inspiratory and expiratory flows of 250 mL/s and a tidal volume of 500 mL. At a pre-determined time during inhalation, the data-acquisition system automatically injected a 10 mL Cl2 bolus into the inspired airflow. Three experiments were conducted during the bolus inhalation session: oral breathing with a peak inhaled Cl2 concentration (cmax) of 3.0 ppm; nasal breathing with a cmaxof 3.0 ppm ; and nasal breathing with a cmax of 0.5 ppm. Anatomic measurements: The anatomy of the respiratory system of each subject was characterised by measurements of FVC (forced vital capacity) by using a forced spirometer, and dead space (VD) by using a nitrogen-washout apparatus. In addition, the nasal volume (VNS), oral volume (VOR), and pharyngeal volume (VPH) of each person were determined by an acoustic reflection apparatus.
- Details on dosing and sampling:
- see detail on study design
- Statistics:
- not indicated.
Results and discussion
- Preliminary studies:
- not indicated.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- In general, the inhaled Cl2 boluses were completely absorbed at a Vp of ~ 80 mL , which was immediately distal to the upper airways. Decreasing Cmax. from 30.0 to 0.5 ppm appears to increase the absorbed fraction of Cl2 at Vp below 60 mL, which is within the hypopharynx. The relationship between VB and Vp is similar for both modes of breathing, with oral values of VB being somewhat larger than nasal values at Vp > 10 mL. Values of σ2 appear relatively insensitive to Vp, with oral values being somewhat larger than nasal values at Vp < 70 mL. The calculated Ka(nasal) averaged for all subjects was significantly larger (P = 0.04) than Ka(oral) (please refer to table A6.2/01 1). On the other hand, there was a significant difference (P = 0.97) between the average Ka(nasal) obtained when cmax. was 0.5 ppm and that when cmax. was 3.0 ppm. The values of Ka(pharyngeal) were 1.5 s-1 during oral breathing of 3.0 ppm Cl2 boluses; 1.1 s-1 during nasal breathing of 3.0 ppm Cl2 boluses; and 1.6 s-1 during nasal breathing of 0.5 ppm Cl2 boluses. This suggests that mass transfer in the hypopharynx was not markedly affected by the mode of breathing or inhaled Cl2 concentration.
- Details on distribution in tissues:
- not indicated.
- Details on excretion:
- not indicated.
Metabolite characterisation studies
- Metabolites identified:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no dataNearly all of the inspired Cl2 was absorbed in the upper airways, and ~ 90 % of the inspired Cl2 was absorbed in the nose or mouth of all the subjects. This result was independent of the mode of breathing and of cmax.
- Executive summary:
To summarise, measurements of the single breath-bolus penetration distribution of Cl2 during nasal as well as oral quiet breathing in five men and five women indicated that > 95 % of inspired Cl2 was absorbed in the upper airways of all subjects, whereas the dose delivered to the respiratory air spaces was negligible. Although there were no statistically significant gender differences in the results, individual values of Ka(oral) were inversely correlated with individual values of VOR. Representative overall mass transfer coefficients estimated in the nose were in good agreement with gas-phase mass transfer coefficients calculated from established correlations. This suggested that diffusional resistance in the nasal mucosa was negligible relative to diffusional resistance in the respired gas. Both the high absorptivity of Cl2 in the upper airways and the domination of the gas-phase diffusion resistance were attributable to the rapid hydrolysis of Cl2in the mucosa.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.